CClinicalTrials.gg
CompletedNCT00569842Updated Sep 11, 2014

Investigation of the Cylex® ImmuKnow® Assay

An observational study in Leukemia, Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, sponsored by Indiana University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-11.

Sponsored by Indiana University School of Medicine · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Study summary

Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.

02

Conditions studied

  • Leukemia
  • Non-Hodgkin's Lymphoma
  • Chronic Lymphocytic Leukemia
  • Hodgkin's Disease
  • Multiple Myeloma
  • Myelodysplastic Syndromes
  • Myeloproliferative Disorders
  • Aplastic Anemia
  • Chronic Myelogenous Leukemia
03

In context

Leukemia

5,442 studies on the registry are indexed under Leukemia; 637 are open to participants now.

This study's enrollment of 45 is below the median of 120 across 744 observational studies indexed under Leukemia.

Browse Leukemia studies →

Lead sponsor

Indiana University School of Medicine is the lead sponsor of 89 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:

  1. Acute leukemia
  2. Non-Hodgkin's Lymphoma
  3. Chronic lymphocytic leukemia
  4. Hodgkin's disease
  5. Multiple myeloma
  6. Myelodysplastic Syndromes
  7. Myeloproliferative Disorders
  8. Aplastic Anemia
  9. Chronic myelogenous leukemia

Eligibility criteria

Inclusion Criteria:

Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:

  1. Acute leukemia
  2. Non-Hodgkin's Lymphoma
  3. Chronic lymphocytic leukemia
  4. Hodgkin's disease
  5. Multiple myeloma
  6. Myelodysplastic Syndromes
  7. Myeloproliferative Disorders
  8. Aplastic Anemia
  9. Chronic myelogenous leukemia
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
45 participants (actual)
Biospecimen retention
None retained

Groups and cohorts

  • observational
06

Study locations

1 site
  • Indiana Universtiy Simon Cancer Center
    Indianapolis, Indiana 46202, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00569842
Lead sponsor
Indiana University School of Medicine
Responsible party
Sponsor
First posted
Dec 7, 2007
Start date
Nov 2007
Primary completion
Feb 2010
Completion
Dec 2012
Last update
Sep 11, 2014

Study contacts

Sherif Farag, MD, PhD
principal investigator · Indiana University School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion